AUTHOR OF THIS BLOG

DR ANTHONY MELVIN CRASTO, WORLDDRUGTRACKER

Perrigo Buying Elan For $8.6B

 companies  Comments Off on Perrigo Buying Elan For $8.6B
Jul 302013
 

U.S. drugmaker Perrigo agreed to buy Ireland’s Elan for $8.6 billion in a deal that should allow the rapidly growing company to reduce its tax bill and boost its royalty stream.

Perrigo Co. said it would pay Elan Corp.’s investors $6.25 per share in cash and $10.25 in Perrigo stock, an 11% premium over Elan’s closing price on July 26. Elan shares in Dublin surged 13% higher to 12.58 euros ($16.71), above Perrigo’s offer price, following news of the takeover.

http://www.dddmag.com/news/2013/07/perrigo-buying-elan-86b

Share

Indian biopharma giant Biocon clocks revenue worth $121 mn

 companies, Uncategorized  Comments Off on Indian biopharma giant Biocon clocks revenue worth $121 mn
Jul 302013
 

 

Kiran Mazumdar-Shaw, chairman and managing director, Biocon.

Indian biopharma giant Biocon reported healthy growth of 22 percent for Q1 FY14 riding on the back of an increased geographical footprint in the emerging markets

 

Bangalore: Indian biopharma giant Biocon reported healthy growth of 22 percent for Q1 FY14. The firm clocked revenues worth $121 million (Rs723 crore), EBITDA of $29.50 million (Rs175 crore); and profit after tax (PAT) of $15.80 million (Rs94 crore).

Read more at: http://www.biospectrumasia.com/biospectrum/news/192549/how-biocon-clock-revenue-worth-usd121-mn#.UfdqX6I3CSo

biocon-s-india-focused-branded-formulations-vertical-as-well-as-research-services-continue-to-grow-at-a-steady-pace

Biocon’s India-focused branded formulations vertical as well as research services continue to grow at a steady pace

Share
Follow

Get every new post on this blog delivered to your Inbox.

Join other followers: